The abstract is read at the publisher; the summary is JClub's.
Recombinant galectin-1 (Gal-1, LGALS1) is enriched in monocytes from myeloproliferative neoplasms and amplifies monocyte inflammatory cytokines via TLR4 and NF-κB.
- Why it matters: Galectin dysregulation is linked to cancer biology, but its specific role in MPN monocyte-driven inflammation and therapeutic targeting remains unclear.
- What they did: Single-cell RNA sequencing and cell-cell communication analyses highlighted galectin gene enrichment in MPN monocytes; mass cytometry and patient CD14+ monocyte assays showed rGal-1 increased inflammatory cytokines, while TLR4 inhibition blocked these effects and NF-κB reporter assays confirmed TLR4-dependent activation.
- The result: In MPLW515L murine MPN, Lgals1 genetic abrogation ameliorated leukocytosis and splenomegaly, and Gal-1 inhibition suppressed carrageenan-induced thrombosis and inflammation, supporting Gal-1 as a therapeutic target.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.